Low-dose tamoxifen reduces recurrence and new breast disease

Bookmark and Share
Published: 12 Dec 2018
Views: 1348
Prof Andrea De Censi - S.C. Oncologia Medica, Genoa, Italy

Prof Andrea De Censi gives a press conference at SABCS 2018 about the results of the phase III TAM-01 clinical trial, where low-dose tamoxifen was found to be safe and effective in reducing recurrence and new breast disease for patients with DCIS, LCIS and ADH. 

Watch his interview with ecancer here.

Read more about this work here